ciprofloxacin has been researched along with Seizures in 33 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Seizures: Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Intravenously administered ciprofloxacin was compared with imipenem for the treatment of severe pneumonia." | 9.07 | Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. ( Caldwell, JW; Fink, MP; Heard, SO; Johnson, RH; Leeper, KV; Niederman, MS; Schentag, JJ; Siami, GA; Snydman, DR; Wunderink, RG, 1994) |
| "Ciprofloxacin-associated seizures (CAS) occur most commonly in patients with special risk factors that may cause accumulation of drug (high doses of the drug, old age, renal insufficiency, drug interactions) or that may decrease the threshold of epileptogenic activity (electrolyte abnormalities, history of seizures, electroconvulsive therapy)." | 8.85 | Ciprofloxacin-associated seizures in a patient with underlying thyrotoxicosis: case report and literature review. ( Agbaht, K; Bayraktar, M; Bitik, B; Piskinpasa, S; Topeli, A, 2009) |
| " Another six days later, she developed breakthrough seizures associated with subtherapeutic serum phenytoin levels." | 7.80 | Ciprofloxacin eye drops-induced subtherapeutic serum phenytoin levels resulting in breakthrough seizures. ( Liew, EK; Malladi, SS; Ng, XT; Tan, RK, 2014) |
| "To determine the pharmacokinetic profile of ciprofloxacin 20 mg/kg per day (10 mg/kg administered intravenously 12 hourly) in paediatric patients with severe sepsis." | 7.71 | Ciprofloxacin pharmacokinetic profiles in paediatric sepsis: how much ciprofloxacin is enough? ( Gous, AG; Hon, H; Lipman, J; Mathivha, LR; Pinder, M; Riera-Fanego, JF; Scribante, J; Stass, H; Tshukutsoane, S; Verhoef, L, 2002) |
| " The effects of some anticonvulsant drugs against seizures induced by a combined treatment with aminophylline and quinolone in genetically epilepsy-prone rat have been investigated." | 7.68 | Only some anticonvulsants protect against seizures induced by aminophylline in quinolone-treated genetically epilepsy prone rats. ( Ammendola, D; De Sarro, A; De Sarro, G; Gareri, P; Juliano, M, 1993) |
| "Five patients had apparently drug-induced seizures while simultaneously receiving theophylline and either imipenem (three patients), ciprofloxacin (one patient), or ciprofloxacin and metronidazole (one patient)." | 7.68 | Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole. ( Allen, N; Semel, JD, 1991) |
| "Intravenously administered ciprofloxacin was compared with imipenem for the treatment of severe pneumonia." | 5.07 | Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. ( Caldwell, JW; Fink, MP; Heard, SO; Johnson, RH; Leeper, KV; Niederman, MS; Schentag, JJ; Siami, GA; Snydman, DR; Wunderink, RG, 1994) |
| "Ciprofloxacin-associated seizures (CAS) occur most commonly in patients with special risk factors that may cause accumulation of drug (high doses of the drug, old age, renal insufficiency, drug interactions) or that may decrease the threshold of epileptogenic activity (electrolyte abnormalities, history of seizures, electroconvulsive therapy)." | 4.85 | Ciprofloxacin-associated seizures in a patient with underlying thyrotoxicosis: case report and literature review. ( Agbaht, K; Bayraktar, M; Bitik, B; Piskinpasa, S; Topeli, A, 2009) |
| "To report two cases of seizures following administration of levofoxacin and ciprofloxacin." | 4.81 | Seizures associated with fluoroquinolones. ( Kushner, JM; Peckman, HJ; Snyder, CR, 2001) |
| " Another six days later, she developed breakthrough seizures associated with subtherapeutic serum phenytoin levels." | 3.80 | Ciprofloxacin eye drops-induced subtherapeutic serum phenytoin levels resulting in breakthrough seizures. ( Liew, EK; Malladi, SS; Ng, XT; Tan, RK, 2014) |
| "To determine the pharmacokinetic profile of ciprofloxacin 20 mg/kg per day (10 mg/kg administered intravenously 12 hourly) in paediatric patients with severe sepsis." | 3.71 | Ciprofloxacin pharmacokinetic profiles in paediatric sepsis: how much ciprofloxacin is enough? ( Gous, AG; Hon, H; Lipman, J; Mathivha, LR; Pinder, M; Riera-Fanego, JF; Scribante, J; Stass, H; Tshukutsoane, S; Verhoef, L, 2002) |
| "A 61-year-old African-American man receiving long-term therapy with phenytoin 100 mg po tid for seizures secondary to a stroke was admitted for community-acquired pneumonia." | 3.69 | Hazards of doubling phenytoin dose in the face of an unrecognized interaction with ciprofloxacin. ( Pollak, PT; Slayter, KL, 1997) |
| " The effect of Ciprofloxacin was studied in electroconvulsive seizures in mice using the tonic extensor phase as end point and seizure threshold as observational parameter." | 3.69 | Interaction of ciprofloxacin with diclofenac and paracetamol in relation to it's epileptogenic effect. ( Makde, SD; Paranjpe, BD; Shrivastava, MP, 1997) |
| " The effects of some anticonvulsant drugs against seizures induced by a combined treatment with aminophylline and quinolone in genetically epilepsy-prone rat have been investigated." | 3.68 | Only some anticonvulsants protect against seizures induced by aminophylline in quinolone-treated genetically epilepsy prone rats. ( Ammendola, D; De Sarro, A; De Sarro, G; Gareri, P; Juliano, M, 1993) |
| "Five patients had apparently drug-induced seizures while simultaneously receiving theophylline and either imipenem (three patients), ciprofloxacin (one patient), or ciprofloxacin and metronidazole (one patient)." | 3.68 | Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole. ( Allen, N; Semel, JD, 1991) |
| "Cerebral actinomycosis is rare and difficult to diagnose." | 1.37 | [Cerebral actinomycosis pseudotumor: a case report]. ( Battikh, R; Ben Abdelhafidh, N; Bougrine, F; Bouziani, A; M'Sadek, F; Madhi, W; Othmani, S; Yedeas, M, 2011) |
| "Different complications were recorded: hydrocephalus and brain abscess in one case, respiratory and hemodynamic failure managed in the intensive care unit in the second, and brain hygroma in the third case." | 1.37 | [Iatrogenic meningitis after diagnosis lumbar puncture: 3 cases reports in the paediatric Children's Hospital of Tunis]. ( Barsaoui, S; Ben Jaballah, N; Bousnina, S; Bouziri, A; Hajji, N; Hariga, D; Kechrid, A; Sammoud, A; Smaoui, H, 2011) |
| "The clinical risk of convulsion for each combination was estimated using a pharmacodynamic model based on receptor occupancy using the in vitro data set obtained and pharmacokinetic parameters in humans collected from the literature." | 1.35 | Quantitative comparison of the convulsive activity of combinations of twelve fluoroquinolones with five nonsteroidal antiinflammatory agents. ( Kim, J; Ohtani, H; Sawada, Y; Tsujimoto, M, 2009) |
| " In addition, concurrent dosing of BPAA (1 microgram/body) did not reduce the convulsion-inducing dose of PZFX mesilate." | 1.31 | [Drug interactions between nonsteroidal anti-inflammatory drug and pazufloxacin mesilate, a new quinolone antibacterial agent for intravenous use: convulsions in mice after intravenous or intracerebroventricular administration]. ( Fukuda, H; Kawamura, Y, 2002) |
| "CSF concentration of ENX at the time of convulsion in clinical situation approximated the IC50 of ENX for the GABA response." | 1.30 | Inhibitory effect of new quinolones on GABA(A) receptor-mediated response and its potentiation with felbinac in Xenopus oocytes injected with mouse-brain mRNA: correlation with convulsive potency in vivo. ( Asanuma, A; Iga, T; Kawakami, J; Sawada, Y; Yamamoto, K; Yanagisawa, K, 1997) |
| "1." | 1.30 | Role of nitric oxide in the convulsive seizures induced by fluoroquinolones coadministered with 4-biphenyl acetic acid. ( Fujimura, H; Kohno, K; Niwa, M; Nozaki, M; Uematsu, T, 1997) |
| "The potential for convulsions induced by the coadministration of ciprofloxacin (CPFX) and foscarnet (PFA) may be due not to a change in the distribution of CPFX to the brain but to a potential CPFX-induced inhibition of gamma-aminobutyric acid (GABA)-GABA(A) receptor binding in the presence of PFA." | 1.30 | Neurotoxicodynamics of the interaction between ciprofloxacin and foscarnet in mice. ( Iga, T; Kawakami, JI; Matsuo, H; Nagata, A; Ryu, M; Sawada, Y; Uchida, T; Yamamoto, K, 1998) |
| "The animals were observed for clonic convulsion and death, and latency times to the appearance of convulsion were determined." | 1.29 | Involvement of inhibitory and excitatory neurotransmitters in levofloxacin- and ciprofloxacin-induced convulsions in mice. ( Akahane, K; Kato, M; Takayama, S, 1993) |
| "Thiopental was administered intravenously with constant infusion rate." | 1.28 | Interaction between ciprofloxacin and thiopental in the central nervous system of the male rat. ( Broholm, KA; Schliamser, SE; Wahlström, G, 1992) |
| "Mice were observed for convulsions for 90 minutes after the administration of temafloxacin HCl (100 mg/kg orally [p." | 1.28 | Assessment of temafloxacin neurotoxicity in rodents. ( Giardina, WJ, 1991) |
| "No convulsion was evoked in mice at high oral combination doses of fleroxacin and fenbufen." | 1.28 | Possibility for induction of convulsion by fleroxacin and its disposition in the central nervous system in animals. ( Hori, S; Kawahara, F; Kobayashi, F; Ooie, T; Saito, S; Sakai, O; Shimada, J; Taga, F; Uchida, H, 1990) |
| " Seizure activity has been reported to occur with the quinolone antibiotics and, with the increasing use of these agents, dose reductions should be kept in mind to avoid potentially serious adverse reactions." | 1.28 | Potential neurologic toxicity related to ciprofloxacin. ( Calvert, JF; Schwartz, MT, 1990) |
| "Ciprofloxacin has been reported to cause theophylline toxicity by inhibiting theophylline metabolism." | 1.28 | Seizure with ciprofloxacin and theophylline combined therapy. ( Bentley, DW; Karki, SD; Raghavan, M, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 22 (66.67) | 18.2507 |
| 2000's | 7 (21.21) | 29.6817 |
| 2010's | 4 (12.12) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Malladi, SS | 1 |
| Liew, EK | 1 |
| Ng, XT | 1 |
| Tan, RK | 1 |
| Darwish, T | 1 |
| Kim, J | 1 |
| Ohtani, H | 1 |
| Tsujimoto, M | 1 |
| Sawada, Y | 3 |
| Agbaht, K | 1 |
| Bitik, B | 1 |
| Piskinpasa, S | 1 |
| Bayraktar, M | 1 |
| Topeli, A | 1 |
| Battikh, R | 1 |
| M'Sadek, F | 1 |
| Bougrine, F | 1 |
| Madhi, W | 1 |
| Ben Abdelhafidh, N | 1 |
| Bouziani, A | 1 |
| Yedeas, M | 1 |
| Othmani, S | 1 |
| Smaoui, H | 1 |
| Hariga, D | 1 |
| Hajji, N | 1 |
| Bouziri, A | 1 |
| Ben Jaballah, N | 1 |
| Barsaoui, S | 1 |
| Bousnina, S | 1 |
| Sammoud, A | 1 |
| Kechrid, A | 1 |
| Abdel-Zaher, AO | 1 |
| Afify, AH | 1 |
| Kamel, SM | 1 |
| Farghaly, HM | 1 |
| El-Osely, GM | 1 |
| El-Awaad, EA | 1 |
| Fukuda, H | 1 |
| Kawamura, Y | 1 |
| Orr, CF | 1 |
| Rowe, DB | 1 |
| Akahane, K | 1 |
| Kato, M | 1 |
| Takayama, S | 1 |
| De Sarro, A | 1 |
| Ammendola, D | 1 |
| Juliano, M | 1 |
| Gareri, P | 1 |
| De Sarro, G | 1 |
| Zhi, J | 1 |
| Nightingale, CH | 1 |
| Fink, MP | 1 |
| Snydman, DR | 1 |
| Niederman, MS | 1 |
| Leeper, KV | 1 |
| Johnson, RH | 1 |
| Heard, SO | 1 |
| Wunderink, RG | 1 |
| Caldwell, JW | 1 |
| Schentag, JJ | 1 |
| Siami, GA | 1 |
| Pollak, PT | 1 |
| Slayter, KL | 1 |
| Brouwers, PJ | 1 |
| de Boer, LE | 1 |
| Guchelaar, HJ | 1 |
| Shrivastava, MP | 1 |
| Makde, SD | 1 |
| Paranjpe, BD | 1 |
| Kawakami, J | 1 |
| Yamamoto, K | 2 |
| Asanuma, A | 1 |
| Yanagisawa, K | 1 |
| Iga, T | 2 |
| Kohno, K | 1 |
| Niwa, M | 1 |
| Nozaki, M | 1 |
| Uematsu, T | 1 |
| Fujimura, H | 1 |
| Springuel, P | 1 |
| Matsuo, H | 1 |
| Ryu, M | 1 |
| Nagata, A | 1 |
| Uchida, T | 1 |
| Kawakami, JI | 1 |
| McLeod, R | 1 |
| Trinkle, R | 1 |
| Tattevin, P | 1 |
| Messiaen, T | 1 |
| Pras, V | 1 |
| Ronco, P | 1 |
| Biour, M | 1 |
| Kushner, JM | 1 |
| Peckman, HJ | 1 |
| Snyder, CR | 1 |
| Lipman, J | 1 |
| Gous, AG | 1 |
| Mathivha, LR | 1 |
| Tshukutsoane, S | 1 |
| Scribante, J | 1 |
| Hon, H | 1 |
| Pinder, M | 1 |
| Riera-Fanego, JF | 1 |
| Verhoef, L | 1 |
| Stass, H | 1 |
| Schliamser, SE | 1 |
| Broholm, KA | 1 |
| Wahlström, G | 1 |
| Dillard, ML | 1 |
| Fink, RM | 1 |
| Parkerson, R | 1 |
| Giardina, WJ | 1 |
| O'Mahony, MS | 1 |
| FitzGerald, MX | 1 |
| Semel, JD | 1 |
| Allen, N | 1 |
| Christ, W | 1 |
| Taga, F | 1 |
| Kobayashi, F | 1 |
| Saito, S | 1 |
| Ooie, T | 1 |
| Kawahara, F | 1 |
| Uchida, H | 1 |
| Shimada, J | 1 |
| Hori, S | 1 |
| Sakai, O | 1 |
| Schwartz, MT | 1 |
| Calvert, JF | 1 |
| Karki, SD | 1 |
| Bentley, DW | 1 |
| Raghavan, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Impact of Aggressive Empiric Antibiotic Therapy and Duration of Therapy on the Emergence of Antimicrobial Resistance During the Treatment of Hospitalized Subjects With Pneumonia Requiring Mechanical Ventilation[NCT01570192] | Phase 2 | 43 participants (Actual) | Interventional | 2010-09-30 | Terminated (stopped due to NIAID terminated the study due to low subject enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: End of treatment - up to 28 days after enrollment
| Intervention | Participants (Count of Participants) |
|---|---|
| ME Group - Meropenem Plus Aminoglycoside | 2 |
| MEGroup - Meropenem Only | 8 |
| m-MITT Group - Meropenem Plus Aminoglycoside | 2 |
| m-MITT Group - Meropenem Only | 8 |
Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: End of treatment - up to 28 days after enrollment
| Intervention | Participants (Count of Participants) |
|---|---|
| ME Group - Meropenem Plus Aminoglycoside | 1 |
| ME Group - Meropenem Only | 2 |
| m-MITT Group - Meropenem Plus Aminoglycoside | 1 |
| m-MITT Group - Meropenem Only | 2 |
Percentage of patients who died by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| ME Group - Meropenem Plus Aminoglycoside | 1 |
| ME Group - Meropenem Only | 0 |
| m-MITT Group - Meropenem Plus Aminoglycoside | 2 |
| m-MITT Group - Meropenem Only | 2 |
Percentage of patients who died by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: 28 days
| Intervention | Participants (Count of Participants) |
|---|---|
| ME Group - Meropenem Plus Aminoglycoside | 2 |
| ME Group - Meropenem Only | 1 |
| m-MITT Group - Meropenem Plus Aminoglycoside | 3 |
| m-MITT Group - Meropenem Only | 3 |
Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: Day 5/Early Extubation
| Intervention | Participants (Count of Participants) |
|---|---|
| ME Group - Meropenem Plus Aminoglycoside | 3 |
| ME Group - Meropenem Only | 6 |
| m-MITT Group - Meropenem Plus Aminoglycoside | 3 |
| m-MITT Group - Meropenem Only | 7 |
Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: End of treatment - up to 28 days after enrollment
| Intervention | Participants (Count of Participants) |
|---|---|
| ME Group - Meropenem Plus Aminoglycoside | 2 |
| ME Group - Meropenem Only | 6 |
| m-MITT Group - Meropenem Plus Aminoglycoside | 2 |
| m-MITT Group - Meropenem Only | 7 |
Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: End of treatment - up to 28 days after enrollment
| Intervention | Participants (Count of Participants) |
|---|---|
| ME Group - Meropenem Plus Aminoglycoside | 3 |
| ME Group - Meropenem Only | 9 |
| m-MITT Group - Meropenem Plus Aminoglycoside | 3 |
| m-MITT Group - Meropenem Only | 11 |
Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: Day 5/Early Extubation
| Intervention | Participants (Count of Participants) |
|---|---|
| ME Group - Meropenem Plus Aminoglycoside | 1 |
| ME Group - Meropenem Only | 1 |
| m-MITT Group - Meropenem Plus Aminoglycoside | 1 |
| m-MITT Group - Meropenem Only | 2 |
The emergence of resistance is defined as a change of meropenem MIC or aminoglycoside MIC by two tube dilutions (fourfold) from baseline when assessed at the second BAL procedure on day 5/early extubation. Patients are evaluable for this endpoint IF they had baseline BAL and Day 5/early extubation and if they had positive cultures on baseline and Day/EE. (NCT01570192)
Timeframe: up to 28 days after enrollment
| Intervention | participants (Number) | |
|---|---|---|
| suppression of emergence of resistance | emergence of resistance | |
| I.V. Meropenem | 5 | 1 |
2 reviews available for ciprofloxacin and Seizures
| Article | Year |
|---|---|
Ciprofloxacin-associated seizures in a patient with underlying thyrotoxicosis: case report and literature review.
Topics: Anti-Infective Agents; Ciprofloxacin; Electroencephalography; Female; Humans; Risk Factors; Seizures | 2009 |
Seizures associated with fluoroquinolones.
Topics: Aged; Anti-Infective Agents; Ciprofloxacin; Female; Humans; Levofloxacin; Magnesium; Ofloxacin; Seiz | 2001 |
1 trial available for ciprofloxacin and Seizures
| Article | Year |
|---|---|
Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.
Topics: Adult; Aged; Anti-Bacterial Agents; Cilastatin; Cilastatin, Imipenem Drug Combination; Ciprofloxacin | 1994 |
30 other studies available for ciprofloxacin and Seizures
| Article | Year |
|---|---|
Ciprofloxacin eye drops-induced subtherapeutic serum phenytoin levels resulting in breakthrough seizures.
Topics: Administration, Oral; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Drug Interactions; Ep | 2014 |
Ciprofloxacin-induced seizures in a healthy patient.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Female; Humans; Recurrence; Seizures; Urinary Tract Inf | 2008 |
Quantitative comparison of the convulsive activity of combinations of twelve fluoroquinolones with five nonsteroidal antiinflammatory agents.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Cipr | 2009 |
[Cerebral actinomycosis pseudotumor: a case report].
Topics: Actinomycosis; Adrenal Cortex Hormones; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacteria | 2011 |
[Iatrogenic meningitis after diagnosis lumbar puncture: 3 cases reports in the paediatric Children's Hospital of Tunis].
Topics: beta-Lactam Resistance; Brain Abscess; Brain Damage, Chronic; Ciprofloxacin; Drug Therapy, Combinati | 2011 |
Involvement of glutamate, oxidative stress and inducible nitric oxide synthase in the convulsant activity of ciprofloxacin in mice.
Topics: Animals; Anti-Infective Agents; Brain; Ciprofloxacin; Dose-Response Relationship, Drug; Glutamic Aci | 2012 |
[Drug interactions between nonsteroidal anti-inflammatory drug and pazufloxacin mesilate, a new quinolone antibacterial agent for intravenous use: convulsions in mice after intravenous or intracerebroventricular administration].
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agent | 2002 |
Eardrop attacks: seizures triggered by ciprofloxacin eardrops.
Topics: Aged; Anti-Infective Agents; Ciprofloxacin; Drug Combinations; Drug Therapy, Combination; Female; Hu | 2003 |
Involvement of inhibitory and excitatory neurotransmitters in levofloxacin- and ciprofloxacin-induced convulsions in mice.
Topics: Acetamides; Alcohol Oxidoreductases; Animals; Ciprofloxacin; Excitatory Amino Acid Antagonists; Inje | 1993 |
Only some anticonvulsants protect against seizures induced by aminophylline in quinolone-treated genetically epilepsy prone rats.
Topics: Aminophylline; Animals; Anticonvulsants; Cinoxacin; Ciprofloxacin; Electroencephalography; Female; M | 1993 |
Biphenylacetate, but not theophylline, lethally interacts with ciprofloxacin in mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Ciprofloxacin; Drug Interactions; Female; Mice; Ph | 1993 |
Hazards of doubling phenytoin dose in the face of an unrecognized interaction with ciprofloxacin.
Topics: Ciprofloxacin; Dose-Response Relationship, Drug; Drug Interactions; Humans; Male; Middle Aged; Pheny | 1997 |
Ciprofloxacin-phenytoin interaction.
Topics: Aged; Anti-Infective Agents; Anticonvulsants; Ciprofloxacin; Drug Interactions; Humans; Male; Phenyt | 1997 |
Interaction of ciprofloxacin with diclofenac and paracetamol in relation to it's epileptogenic effect.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Anti-Infective Agents; Anti-Inflammatory Agents, N | 1997 |
Inhibitory effect of new quinolones on GABA(A) receptor-mediated response and its potentiation with felbinac in Xenopus oocytes injected with mouse-brain mRNA: correlation with convulsive potency in vivo.
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Bicuculline; Brain Chemistr | 1997 |
Role of nitric oxide in the convulsive seizures induced by fluoroquinolones coadministered with 4-biphenyl acetic acid.
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Ciprofloxacin; Convulsants; | 1997 |
Risk of seizures from concomitant use of ciprofloxacin and phenytoin in patients with epilepsy.
Topics: Anti-Infective Agents; Anticonvulsants; Ciprofloxacin; Drug Interactions; Epilepsy; Humans; Phenytoi | 1998 |
Neurotoxicodynamics of the interaction between ciprofloxacin and foscarnet in mice.
Topics: Animals; Anti-Infective Agents; Antiviral Agents; Brain; Ciprofloxacin; Drug Interactions; Foscarnet | 1998 |
Comment: unexpectedly low phenytoin concentration in a patient receiving ciprofloxacin.
Topics: Aged; Anti-Infective Agents; Anticonvulsants; Ciprofloxacin; Drug Interactions; Female; Humans; Phen | 1998 |
Confusion and general seizures following ciprofloxacin administration.
Topics: Anti-Infective Agents; Ciprofloxacin; Confusion; Follow-Up Studies; Humans; Kidney Failure, Chronic; | 1998 |
Ciprofloxacin pharmacokinetic profiles in paediatric sepsis: how much ciprofloxacin is enough?
Topics: Anti-Infective Agents; Child, Preschool; Ciprofloxacin; Female; Humans; Infant; Injections, Intraven | 2002 |
Interaction between ciprofloxacin and thiopental in the central nervous system of the male rat.
Topics: Animals; Central Nervous System; Ciprofloxacin; Drug Interactions; Electroencephalography; Infusions | 1992 |
Ciprofloxacin-phenytoin interaction.
Topics: Aged; Ciprofloxacin; Drug Interactions; Humans; Male; Phenytoin; Seizures | 1992 |
Assessment of temafloxacin neurotoxicity in rodents.
Topics: Animals; Anti-Infective Agents; Central Nervous System; Ciprofloxacin; Enoxacin; Fluoroquinolones; M | 1991 |
Cystic fibrosis and seizures.
Topics: Adult; Ciprofloxacin; Cystic Fibrosis; Humans; Seizures; Theophylline | 1991 |
Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole.
Topics: Aged; Ciprofloxacin; Drug Interactions; Drug Therapy, Combination; Epilepsies, Partial; Female; Huma | 1991 |
Central nervous system toxicity of quinolones: human and animal findings.
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Central Nervous System; Cip | 1990 |
Possibility for induction of convulsion by fleroxacin and its disposition in the central nervous system in animals.
Topics: Animals; Brain; Central Nervous System; Ciprofloxacin; Cisterna Magna; Dogs; Fleroxacin; In Vitro Te | 1990 |
Potential neurologic toxicity related to ciprofloxacin.
Topics: Aged; Bacterial Infections; Ciprofloxacin; Female; Humans; Nervous System Diseases; Seizures | 1990 |
Seizure with ciprofloxacin and theophylline combined therapy.
Topics: Aged; Aged, 80 and over; Ciprofloxacin; Drug Therapy, Combination; Female; Humans; Male; Seizures; T | 1990 |